WallStSmart
TELO

Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ: TELO · HEALTHCARE · BIOTECHNOLOGY

$1.29
+3.25% today

Updated 2026-06-04

Market cap
$86.66M
P/E ratio
P/S ratio
EPS (TTM)
$-0.29
Dividend yield
52W range
$1 – $3
Volume
0.1M

Telomir Pharmaceuticals, Inc. Common Stock (TELO) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20212022202320242025
Total assets$55000.00$48730.00$4.77M$1.32M$7.34M
Cash & equivalents$0.00$1419.00$1231.00$1.27M$7.29M
Current assets$0.00$48730.00$435225.00$1.32M$7.34M
Total liabilities$138131.00$986008.00$1.34M$680968.00$1.43M
Current liabilities$138131.00$986008.00$1.34M$680968.00$1.43M
Long-term debt
Shareholder equity$-83131.00$-937278.00$3.44M$643037.00$5.91M
Retained earnings$-138131.00$-992278.00$-14.06M$-30.60M$-41.01M
Accounts receivable$130000.00
Inventory$303281.00
Goodwill

Frequently asked questions

How much free cash flow does TELO generate?

TELO produced $-3.69M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is TELO's balance sheet healthy?

TELO holds $7.29M in cash and equivalents against — in long-term debt, on $5.91M of shareholder equity. That debt is best read against the cash flow the business throws off each year.